Psychemedics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Psychemedics hat ein Gesamteigenkapital von $5.7M und eine Gesamtverschuldung von $781.0K, was einen Verschuldungsgrad von 13.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $10.1M bzw. $4.4M.

Wichtige Informationen

13.6%

Verhältnis von Schulden zu Eigenkapital

US$781.00k

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$1.43m
Eigenkapital	US$5.74m
Gesamtverbindlichkeiten	US$4.37m
Gesamtvermögen	US$10.11m

Jüngste Berichte zur Finanzlage

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05

Recent updates

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Jul 29

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Jan 08

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

May 13

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Aug 09

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Apr 25

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Nov 18

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Oct 18

Psychemedics reports Q1 results

May 10

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

May 07

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Mar 05

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Jan 30

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

Jan 11

Psychemedics reports Q3 results

Nov 09

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PMDDie kurzfristigen Aktiva des Unternehmens ($6.0M) übersteigen seine kurzfristigen Passiva ($3.7M).

Langfristige Verbindlichkeiten: PMDDie kurzfristigen Vermögenswerte des Unternehmens ($6.0M) übersteigen seine langfristigen Verbindlichkeiten ($623.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PMD über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: PMDDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 7.7% auf 13.6% gestiegen.

Schuldendeckung: PMDDer operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von PMD für seine Schulden durch das EBIT gut gedeckt sind.

Psychemedics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Recent updates

Psychemedics Corporation Launches New Ketamine Hair Testing Service

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.13 loss in 2Q 2023)

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New minor risk - Share price stability

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New major risk - Market cap size

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.068 loss in 1Q 2023)

Full year 2023 earnings released: US$0.72 loss per share (vs US$0.19 loss in FY 2022)

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.017 loss in 3Q 2022)

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.06 loss in 2Q 2022)

New minor risk - Shareholder dilution

Psychemedics Corporation, Annual General Meeting, Aug 17, 2023

Psychemedics Corporation Announces Board Changes

Upcoming dividend of US$0.07 per share at 5.6% yield

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.007 profit in 1Q 2022)

Psychemedics Corporation Declares Cash Dividend, Payable on June 8, 2023

Full year 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in FY 2021)

Psychemedics Corporation Appoints William Norris as Controller of the Company, Effective as of January 1, 2023

Upcoming dividend of US$0.07 per share

Third quarter 2022 earnings released: US$0.017 loss per share (vs US$0.13 profit in 3Q 2021)

Third quarter 2022 earnings released: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)

Psychemedics Corporation Declares Quarterly Cash Dividend, Payable on December 16, 2022

Psychemedics Corporation Announces Executive Changes

Upcoming dividend of US$0.07 per share

Second quarter 2022 earnings released: US$0.06 loss per share (vs US$0.024 profit in 2Q 2021)

Psychemedics Corporation Announces Quarterly Dividend, Payable on September 9, 2022

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics Corporation, Annual General Meeting, Aug 12, 2022

Upcoming dividend of US$0.07 per share

First quarter 2022 earnings: EPS exceeds analyst expectations

Psychemedics Corporation Declares Cash Dividend for First Quarter Ended March 31, 2022, Payable on June 24, 2022

Insider recently bought US$268k worth of stock

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Insider recently bought US$268k worth of stock

Insider recently bought US$112k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Insider recently bought US$393k worth of stock

Psychemedics Corporation Enters into Binding Memorandum of Understanding to Settle Purported Class Action Lawsuit Against It Related to Certain California Wage and Hour Laws

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.20 loss in 3Q 2020)

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Insider recently bought US$76k worth of stock

Insider recently bought US$728k worth of stock

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.37 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.029 loss in 1Q 2020)

Psychemedics reports Q1 results

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

Full year 2020 earnings released: US$0.70 loss per share (vs US$0.28 profit in FY 2019)

Psychemedics Corporation Elects Robyn C. Davis on the Board of Director, Effective Immediately

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

New 90-day high: US$7.45

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

New 90-day high: US$5.36

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

New 90-day high: US$5.14

Insider recently bought US$258k worth of stock

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

New 90-day high: US$4.95

Psychemedics Corporation Announces Resignation of Neil L. Lerner as Its Vice President-Finance, Treasurer and Assistant Secretary of the Corporation, Effective November 27, 2020

Third quarter 2020 earnings released: US$0.20 loss per share

Psychemedics reports Q3 results

New 90-day low: US$3.99

New 90-day low: US$4.30